Infinant Health raised $39.25 million to advance INF108, an FDA-designated orphan drug and rare pediatric disease-designated live biotherapeutic for the prevention of necrotizing enterocolitis, a rare and life-threatening intestinal condition primarily affecting preterm infants.
